Quanterix Corporation - QTRX STOCK NEWS

The FDA's recent approval of tofersen for treating SOD1-ALS marks a significant milestone, supported by compelling blood-based neurofilament light chain (NfL) measurements. This is the first instance of a blood biomarker being utilized as a surrogate endpoint for accelerated drug approval in neurology. Tofersen, which reduces the overproduction of SOD1 protein, demonstrated trends toward clinical benefit despite not significantly slowing disease progression in Phase III trials. The approach of using NfL measurements opens new avenues for neurodegenerative disease research and treatment, potentially impacting various conditions like Alzheimer's and multiple sclerosis. Quanterix Corporation, the developer of the Simoa NfL assay, plays a crucial role in this breakthrough, advancing biomarker use in clinical management.

Quanterix Corporation (NASDAQ: QTRX), a leader in biomarker detection, has announced that CEO Masoud Toloue will present at the Barclays Global Healthcare Conference on March 15, 2023, at 4:35 p.m. EDT. The company will also conduct one-on-one meetings with institutional investors on the same day. Investors can register for a virtual presentation via the provided link. Following the conference, the presentation and webcast will be accessible on Quanterix’s website. Quanterix is recognized for its Simoa® technology, which revolutionizes biomarker detection and supports significant research across various diseases.

Quanterix Corporation (NASDAQ: QTRX) announced its financial results for Q4 and the full year ended December 31, 2022. The company reported a Q4 GAAP revenue of $25.8 million, a 14.7% decline from the previous year, while full-year revenue was $105.5 million, down from $110.6 million in 2021. The gross margin for Q4 was 48.8%, improved from 41.1% in Q3 2022. The company reported an operating loss of $22.3 million, influenced by $10 million in restructuring costs. Despite the setbacks, the CEO noted progress in their strategic business realignment and promising advancements in Alzheimer's diagnostics.

Quanterix Corporation (NASDAQ: QTRX) announced that its CEO, Masoud Toloue, will present at Cowen’s 43rd Annual Health Care Conference on March 7, 2023, at 9:50 a.m. EST. The conference occurs from March 6-8, 2023, at the Boston Marriott Copley Place. Quanterix will host one-on-one meetings with institutional investors during the event. The presentation will be available via live audio webcast, and replays will be accessible afterward on the company's investor relations page. Quanterix specializes in ultrasensitive biomarker detection through its Simoa® technology, contributing to advancements in various fields including neurology and oncology.

Quanterix Corporation (NASDAQ: QTRX) announced a conference call scheduled for March 6, 2023, at 8:30 AM Eastern Time to discuss its fourth quarter and full year 2022 financial results. The call will be led by Masoud Toloue, President and CEO, and Michael Doyle, CFO. A press release with detailed earnings information will precede the call, available on the Quanterix website. Quanterix specializes in ultrasensitive biomarker detection, leveraging its Simoa® technology for breakthroughs in various disease areas. The company has been a longstanding partner in scientific research, contributing to over 2,000 peer-reviewed journals.

NATICK, Mass. - Mercy BioAnalytics announced that Dawn Mattoon, PhD, has taken over as Chief Executive Officer, transitioning from her previous role as Chief Operating Officer. Paul Blavin has moved to the position of Vice Chairman of the Board. Dr. Mattoon, who has been with the company for seven months, praised the team's progress in advancing their cancer detection technology. Her experience includes leadership roles in strategic initiatives at companies like Quanterix and Thermo Fisher Scientific. The company focuses on the early detection of cancers, particularly ovarian and lung cancers, through its Mercy Halo liquid biopsy platform.

Quanterix Corporation (NASDAQ: QTRX) appointed Brian Blaser to its Board of Directors on January 6, 2023. With over 25 years in the in-vitro diagnostics field, including 15 years at Abbott Laboratories, Blaser's leadership experience enhances the board's expertise. He has a proven track record in launching diagnostic products and implementing growth strategies. CEO Masoud Toloue emphasized Blaser's operational excellence, which aligns with Quanterix’s future diagnostics initiatives. Blaser holds an MBA from the Rochester Institute of Technology and a Bachelor's in Mechanical Engineering Technology from the University of Dayton.

Quanterix Corporation (NASDAQ: QTRX) has announced the validation of a new CLIA blood test to quantitatively measure neurofilament light chain (NfL) levels in serum. This test aids in assessing neurodegenerative conditions and neuronal damage. NfL is a crucial biomarker for various neurological disorders, and the Simoa NfL test is widely recognized for its clinical relevance. The FDA previously granted Breakthrough Device designation for this test in relation to multiple sclerosis. This launch aims to enhance clinical diagnostics and support future therapeutic trials.